Skip to Main content
  • Prescribing Information
  • Patient Site
Ubrelvy Logo
  • Ubrelvy Logo
  • Efficacy
    • Study Design
  • Safety
  • Dosing
  • How UBRELVY Works
  • Impact of UBRELVY
  • Access
  • Resources
Request Samples
Request a Rep
Speaker Programs
Request Samples
Request a Rep
Speaker Programs

UBRELVY SITE MAP


  • Home
  • Efficacy
    • Study Design
  • Safety
  • Dosing
  • How UBRELVY Works
  • Impact of UBRELVY
  • Access
  • Resources
  • Prescribing Information
  • Patient Site
  • Privacy Statement
  • Contact Us

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Drug Interactions:

  • Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
  • Dose modifications are recommended when using the following:
    1. Moderate or weak CYP3A4 inhibitors and inducers
    2. BCRP and/or P-gp only inhibitors

Dosage and Administration:

  • The recommended dose is 50 mg or 100 mg taken orally, as needed.
  • If needed, a second dose may be administered at least 2 hours after the initial dose.
  • The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
  • Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
  • Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive
treatment of migraine.

Please see full Prescribing Information.

  • Privacy Statement
  • Terms of Use
  • Contact Us
  • Site Map
  • Cookies Settings

UBRELVY® and its design are registered trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.

© 2022 AbbVie. All rights reserved.

US-UBR-220090 10/20

This site is intended for US healthcare professionals only.

US-UBR-220090 12/22

Abbvie  Logo

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

IMPORTANT SAFETY INFORMATION

Contraindication: Concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Adverse Reactions: The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Drug Interactions:

  • Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
  • Dose modifications are recommended when using the following:
    1. Moderate or weak CYP3A4 inhibitors and inducers
    2. BCRP and/or P-gp only inhibitors

Dosage and Administration:

  • The recommended dose is 50 mg or 100 mg taken orally, as needed.
  • If needed, a second dose may be administered at least 2 hours after the initial dose.
  • The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.
  • Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose.
  • Avoid use in patients with end-stage renal disease.

INDICATION

UBRELVY® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive
treatment of migraine.

Please see full Prescribing Information.